SAN DIEGO, July 14, 2015 /PRNewswire/ -- OncoSec Medical
Inc. ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based
intratumoral cancer immunotherapies, announced today that
Robert H. Pierce, MD, Chief
Scientific Officer, will participate in a BioPharma Dealmakers
webcast featuring four companies developing cancer immunotherapies.
The webcast is scheduled for 11:00 am
ET on July 21, 2015. To
register for the webcast, please click here.
The webcast will explore some of the challenges and
opportunities of technologies at the cutting edge of cancer
immunotherapy. Participants will learn about new approaches that
have been developed to:
- Harness the full potential of our immune system
- Screen for novel target and antibody combinations
- Enlist our own immune system to attack cancer cells
- Improve the delivery of cancer-specific therapeutics to
tumors
The webcast will include a round table discussion and a Q&A
session to enable participants to contribute their own thoughts on
this highly innovative area of cancer research. The webcast is
sponsored in part by OncoSec. In addition to Dr. Pierce, other
webcast participants include:
- Jeremy Graff, PhD, Senior Vice
President, Pharmaceutical Research for Biothera. Dr. Graff joined
Biothera from Eli Lilly and Company where he was Research Fellow
and Group Leader, Oncology Patient Tailoring.
- Björn Frendéus, PhD, Chief Scientific Officer, BioInvent. Dr.
Frendéus is an immunologist and graduate of the Swedish Foundation
for Strategic Research.
- Harlan Robins, PhD, Adaptive
Biotechnologies. Dr. Robins is the Chief Scientific Officer and
Co-Founder of Adaptive Biotechnologies.
- Moderator: Gaspar
Taroncher-Oldenburg, PhD. Dr. Taroncher-Oldenburg is an
independent consultant and former managing editor of SciBX:
Science-Business eXchange for Nature Publishing Group and the
former scientific editor at Nature Biotechnology.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a
biopharmaceutical company developing its investigational
ImmunoPulse™ intratumoral cancer immunotherapy. OncoSec's core
technology is designed to enhance the local delivery and uptake of
DNA IL-12 and other DNA-based immune-targeting agents. Clinical
studies of ImmunoPulse™ IL-12 have demonstrated an acceptable
safety profile and evidence of anti-tumor activity in the treatment
of various skin cancers as well as the potential to initiate a
systemic immune response. OncoSec's lead program, ImmunoPulse™
IL-12, is currently in Phase II development for several
indications, including metastatic melanoma and squamous cell
carcinoma of the head and neck. In addition to ImmunoPulse™ IL-12,
the company is also identifying and developing new immune-targeting
agents for use with the ImmunoPulse™ platform. For more
information, please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such "forward-looking statements."
Forward-looking statements are based on management's current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical's filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
About the Webcast
Biopharma Dealmakers webcasts
are dedicated to small and large companies looking for commercial
partnerships. Read the quarterly Biopharma Dealmakers supplement in
Nature Biotechnology and Nature Reviews Drug
Discovery.
CONTACT:
Investor Relations:
Jordyn Kopin
OncoSec Medical Inc.
855-662-6732
investors@oncosec.com
Media Relations:
Mary Marolla
OncoSec Medical Inc.
855-662-6732
media@oncosec.com
Logo -
http://photos.prnewswire.com/prnh/20120905/LA68078LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/oncosec-medical-to-participate-in-webcast-on-advances-in-cancer-immunotherapy-300112751.html
SOURCE OncoSec Medical Inc.